{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:38Z","timestamp":1786725758032,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Disease-modifying agents like Pioglitazone have shown promising effects on neuroinflammation and homeostasis of amyloid plaques, but there is a lack of research papers providing conclusive evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study is aimed to determine the safety and efficacy of Pioglitazone in improving cognitive function in patients with mild-moderate Alzheimer's disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Trials published in the last 12 years were identified from PubMed, Scopus, Cochrane Central, and other trial registries. Five hundred twenty-five records were obtained, from which five studies were included for quantitative analysis. Studies comparing Pioglitazone with a suitable placebo or other oral hypoglycemic agent were considered for review. Data was extracted using a pretested form, which was followed by a risk of bias assessment (ROB) with Cochrane's ROB assessment tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This meta-analysis included studies where Pioglitazone (15\u201330 mg) was compared to other oral hypoglycemic agents, placebo, or diabetic diet for a minimum duration of 6 months. Pioglitazone did not show a statistically significant improvement in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores [mean difference (MD): \u22121.16; 95% confidence interval (CI): \u22124.14\u20131.81]. By conducting sensitivity analysis with the removal of one study, significant efficacy was obtained [MD: \u22122.75; 95% CI: \u22124.84\u2013\u22120.66]. The Wechsler Memory Scale-Revised logical memory I (WMS-R) scores had a significant improvement in the Pioglitazone group [MD: 2.02; 95% CI: 0.09\u20133.95].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pioglitazone is a safe medication that has a promising effect in slowing the advancement of AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.391397","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T11:03:40Z","timestamp":1704279820000},"page":"1132-1141","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Drug Repositioning of Pioglitazone in Management and Improving the Cognitive Function among the Patients with Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.4103","volume":"71","author":[{"given":"Roopa S.","family":"Basutkar","sequence":"first","affiliation":[{"name":"Nitte (Deemed to be University) NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmacy Practice, Mangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Sudarsan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Robin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahini","family":"Bhaskar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasubramaniam","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Department of Surgery, Government Medical College and Hospital, Ooty, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponnusankar","family":"Sivasankaran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"R1-20260511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-30487-6","article-title":"IL-1\u03b2, IL-6, TNF- \u03b1 and CRP in elderly patients with depression or Alzheimer's disease: Systematic review and meta-analysis","volume":"8","author":"Ng","year":"2018","journal-title":"Sci Rep"},{"key":"R2-20260511","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3233\/JAD-161149","article-title":"Recent progress in Alzheimer's disease research, Part 2: Genetics and epidemiology","volume":"57","author":"Robinson","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"R3-20260511","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimer's Dement"},{"key":"R4-20260511","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Nichols","year":"2019","journal-title":"Lancet Neurol"},{"key":"R6-20260511","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2004.02.048","article-title":"Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease","volume":"490","author":"Watson","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"R7-20260511","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/dom.13373","article-title":"Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis","volume":"20","author":"Cao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R8-20260511","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-8587(13)70125-6","article-title":"Diabetes drugs and neurological disorders: New views and therapeutic possibilities","volume":"2","author":"Patrone","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R9-20260511","first-page":"1","article-title":"Changing the natural history of type 2 diabetes: Implications for clinical care","volume":"38","author":"Alliot","year":"2016","journal-title":"Q Themat J Clin Ther Res"},{"key":"R10-20260511","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1042\/BJ20050560","article-title":"Role of peroxisome proliferator-activated receptor \u03b3 in amyloid precursor protein processing and amyloid \u03b2-mediated cell death","volume":"391","author":"D'Abramo","year":"2005","journal-title":"Biochem J"},{"key":"R11-20260511","doi-asserted-by":"crossref","first-page":"403896","DOI":"10.1155\/2008\/403896","article-title":"PPARs in Alzheimer's disease","volume":"2008","author":"Kummer","year":"2008","journal-title":"PPAR Res"},{"key":"R12-20260511","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jdiacomp.2013.03.005","article-title":"Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND","volume":"27","author":"Seaquist","year":"2013","journal-title":"J Diabetes Complications"},{"key":"R13-20260511","doi-asserted-by":"crossref","first-page":"957248","DOI":"10.1155\/2015\/957248","article-title":"Therapeutic actions of the thiazolidinediones in Alzheimer's disease","volume":"2015","author":"P\u00e9rez","year":"2015","journal-title":"PPAR Res"},{"key":"R14-20260511","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13543784.2017.1265504","article-title":"Pioglitazone for the treatment of Alzheimer's disease","volume":"26","author":"Galimberti","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"R15-20260511","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1345\/aph.1Q238","article-title":"Rosiglitazone and Pioglitazone for the treatment of Alzheimer's disease","volume":"45","author":"Miller","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R16-20260511","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1038\/s41598-019-40736-x","article-title":"Low-dose Pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus","volume":"9","author":"Seok","year":"2019","journal-title":"Sci Rep"},{"key":"R17-20260511","first-page":"4113","article-title":"Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease","volume":"17","author":"Ma","year":"2018","journal-title":"Mol Med Rep"},{"key":"R18-20260511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2018.00037","article-title":"Challenges for Alzheimer's disease therapy: Insights from novel mechanisms beyond memory defects","volume":"12","author":"Frozza","year":"2018","journal-title":"Front Neurosci"},{"key":"R19-20260511","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/anie.200802808","article-title":"Alzheimer's disease: From pathology to therapeutic approaches","volume":"48","author":"Roland","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"R20-20260511","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1532-5415.2010.02841.x","article-title":"The role of tumor necrosis factor-alpha in cognitive improvement after Peroxisome Proliferator-Activator Receptor Gamma agonist Pioglitazone treatment in Alzheimer's disease","volume":"58","author":"Hanyu","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"R21-20260511","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1532-5415.2009.02067.x","article-title":"Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus","volume":"56","author":"Hanyu","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"R22-20260511","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","article-title":"Efficacy of PPAR-\u03b3 agonist Pioglitazone in mild Alzheimer disease","volume":"32","author":"Sato","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"1","key":"R23-20260511","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000371509","article-title":"Effects of Pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: A pilot study","volume":"5","author":"Hildreth","year":"2015","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"R24-20260511","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A randomized pilot clinical trial of the safety of Pioglitazone in treatment of patients with alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Arch Neurol"},{"key":"R25-20260511","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/156720507780362137","article-title":"Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment","volume":"4","author":"Craft","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"R26-20260511","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200317010-00003","article-title":"The role of the insulin resistance in the pathogenesis of Alzheimer's disease","volume":"17","author":"Watson","year":"2003","journal-title":"CNS Drugs"},{"key":"R27-20260511","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/156720507780362092","article-title":"Therapeutic use of agonists of the nuclear receptor PPAR\u03b3 in Alzheimer's disease","volume":"4","author":"Landreth","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"R28-20260511","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.it.2007.09.003","article-title":"Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms","volume":"28","author":"Straus","year":"2007","journal-title":"Trends Immunol"},{"key":"R29-20260511","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R30-20260511","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of Rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"R31-20260511","first-page":"950","article-title":"Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone","volume":"13","author":"Watson","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"R32-20260511","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.trci.2019.05.004","article-title":"Effects of Pioglitazone on mnemonic hippocampal function: A blood oxygen level\u2013dependent functional magnetic resonance imaging study in elderly adults","volume":"5","author":"Knodt","year":"2019","journal-title":"Alzheimer's Dement Transl Res Clin Interv"},{"key":"R34-20260511","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archneur.63.11.1551","article-title":"Diabetes Mellitus and Risk of Developing Alzheimer Disease","volume":"63","author":"Akomolafe","year":"2006","journal-title":"Arch Neurol"},{"key":"R35-20260511","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.2040-1124.2010.00046.x","article-title":"Relationship between urinary sodium excretion and Pioglitazone-induced edema","volume":"1","author":"Nakamura","year":"2010","journal-title":"J Diabetes Investig"},{"key":"R36-20260511","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione Use, fluid retention, and congestive heart failure","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"R37-20260511","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JAD-2008-15312","article-title":"Administration and Scoring Variance on the ADAS-Cog","volume":"15","author":"Connor","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"R38-20260511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200822010-00001","article-title":"The role of peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) in Alzheimer's disease: Therapeutic implications","volume":"22","author":"Jiang","year":"2008","journal-title":"CNS Drugs"},{"key":"R39-20260511","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/gps.2679","article-title":"Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease","volume":"27","author":"Ihl","year":"2012","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.391397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:19Z","timestamp":1786724719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.391397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.391397","relation":{},"ISSN":["0028-3886","1998-4022"],"issn-type":[{"value":"0028-3886","type":"print"},{"value":"1998-4022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"2022-07-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}